Treatment Options for Tauopathies

被引:28
作者
Karakaya, Tarik [1 ]
Fusser, Fabian [1 ]
Prvulovic, David [1 ]
Hampel, Harald [1 ]
机构
[1] Goethe Univ Frankfurt, Dept Psychiat, D-60528 Frankfurt, Germany
关键词
Tauopathies; Tau proteins; Neurodegenerative diseases; PSP; Progressive supranuclear palsy; FTD; Corticobasal degeneration; Treatment; Dementia; Parkinson plus syndromes; SSRIs; Acetylcholinesterase inhibitors; Antipsychotics; Trazodone; Memantine; Levodopa; FRONTOTEMPORAL LOBAR DEGENERATION; PROGRESSIVE SUPRANUCLEAR PALSY; OPEN-LABEL; CONTROLLED-TRIAL; DOUBLE-BLIND; DEMENTIA; RIVASTIGMINE; PAROXETINE; MEMANTINE; SYMPTOMS;
D O I
10.1007/s11940-012-0168-7
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
To date, there are no approved and established pharmacologic treatment options for tauopathies, a very heterogenous group of neuropsychiatric diseases often leading to dementia and clinically diagnosed as atypical Parkinson syndromes. Among these so-called Parkinson plus syndromes are progressive supranuclear palsy (PSP), also referred to as Steele-Richardson-Olszewski syndrome; frontotemporal dementia (FTD); and corticobasal degeneration (CBD). Available treatment strategies are based mainly on small clinical trials, miscellaneous case reports, or small case-controlled studies. The results of these studies and conclusions about the efficacy of the medication used are often contradictory. Approved therapeutic agents for Alzheimer' s dementia, such as acetylcholinesterase inhibitors and memantine, have been used off-label to treat cognitive and behavioral symptoms in tauopathies, but the outcome has not been consistent. Therapeutic agents for the symptomatic treatment of Parkinson's disease (levodopa or dopamine agonists) are used for motor symptoms in tauopathies. For behavioral or psychopathological symptoms, treatment with antidepressants-especially selective serotonin reuptake inhibitors-could be helpful. Antipsychotics are often not well tolerated because of their adverse effects, which are pronounced in tauopathies; these drugs should be given very carefully because of an increased risk of cerebrovascular events. In addition to pharmacologic options, physical, occupational, or speech therapy can be applied to improve functional abilities. Each pharmacologic or nonpharmacologic intervention should be fitted to the specific symptoms of the individual patient, and decisions about the type and duration of treatment should be based on its efficacy for the individual and the patient's tolerance. Currently, no effective treatment is available that targets the cause of these diseases. Current research focuses on targeting tau protein pathology, including pathologic aggregation or phosphorylation; these approaches seem to be very promising.
引用
收藏
页码:126 / 136
页数:11
相关论文
共 44 条
[1]   Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial [J].
Aarsland, Dag ;
Ballard, Clive ;
Walker, Zuzana ;
Bostrom, Fredrik ;
Alves, Guido ;
Kossakowski, Katja ;
Leroi, Iracema ;
Pozo-Rodriguez, Francisco ;
Minthon, Lennart ;
Londos, Elisabet .
LANCET NEUROLOGY, 2009, 8 (07) :613-618
[2]   An Open-label Study of Memantine Treatment in 3 Subtypes of Frontotemporal Lobar Degeneration [J].
Boxer, Adam L. ;
Lipton, Anne M. ;
Womack, Kyle ;
Merrilees, Jennifer ;
Neuhaus, John ;
Pavlic, Danijela ;
Gandhi, Anisha ;
Red, Dana ;
Martin-Cook, Kristen ;
Svetlik, Doris ;
Miller, Bruce L. .
ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 2009, 23 (03) :211-217
[3]   Paroxetine in Parkinson's disease: Effects on motor and depressive symptoms [J].
Ceravolo, R ;
Nuti, A ;
Piccinni, A ;
Dell'Agnello, G ;
Bellini, G ;
Gambaccini, G ;
Dell'Osso, L ;
Murri, L ;
Bonuccelli, U .
NEUROLOGY, 2000, 55 (08) :1216-1218
[4]   Mitochondrial Approaches for Neuroprotection [J].
Chaturvedi, Rajnish K. ;
Beal, M. Flint .
MITOCHONDRIA AND OXIDATIVE STRESS IN NEURODEGENERATIVE DISORDERS, 2008, 1147 :395-412
[5]   Open-label study of the short-term effects of memantine on FDG-PET in frontotemporal dementia [J].
Chow, Tiffany W. ;
Graff-Guerrero, Ariel ;
Verhoeff, Nicolaas P. L. G. ;
Binns, Malcolm A. ;
Tang-Wai, David F. ;
Freedman, Morris ;
Masellis, Mario ;
Black, Sandra E. ;
Wilson, Alan A. ;
Houle, Sylvain ;
Pollock, Bruce G. .
NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2011, 7 :415-424
[6]   Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial [J].
Deakin, JB ;
Rahman, S ;
Nestor, PJ ;
Hodges, JR ;
Sahakian, BJ .
PSYCHOPHARMACOLOGY, 2004, 172 (04) :400-408
[7]   A 6-month, open-label study of memantine in patients with frontotemporal dementia [J].
Diehl-Schmid, Janine ;
Foerstl, Hans ;
Perneczky, Robert ;
Pohl, Corina ;
Kurz, Alexander .
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2008, 23 (07) :754-759
[8]   Rivastigmine for dementia associated with Parkinson's disease [J].
Emre, M ;
Aarsland, D ;
Albanese, A ;
Byrne, EJ ;
Deuschl, G ;
De Deyn, PP ;
Durif, F ;
Kulisevsky, J ;
van Laar, T ;
Lees, A ;
Poewe, W ;
Robillard, A ;
Rosa, MM ;
Wolters, E ;
Quarg, P ;
Tekin, S ;
Lane, R .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (24) :2509-2518
[9]   Parkinsonism and Frontotemporal Dementia: The Clinical Overlap [J].
Espay, Alberto J. ;
Litvan, Irene .
JOURNAL OF MOLECULAR NEUROSCIENCE, 2011, 45 (03) :343-349
[10]   Clinical improvement in a case of frontotemporal dementia under aripiprazole treatment corresponds to partial recovery of disturbed frontal glucose metabolism [J].
Fellgiebel, Andreas ;
Mueller, Matthias J. ;
Hiemke, Christoph ;
Bartenstein, Peter ;
Schreckenberger, Matthias .
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2007, 8 (02) :123-126